Penston J G, Wormsley K G
Ninewells Hospital & Medical School, Dundee, Scotland, UK.
Aliment Pharmacol Ther. 1990 Aug;4(4):339-55. doi: 10.1111/j.1365-2036.1990.tb00481.x.
One hundred and twenty patients with gastric ulcer disease, who had been receiving maintenance treatment with ranitidine (150 or 300 mg/day) for periods up to 7 years, were studied retrospectively. The proportion of patients remaining free from symptomatic recurrence of ulcer during maintenance treatment was 97% after 1 year; 90% after 3 years; and 79% after 5 years. No patient developed haemorrhage or perforation during maintenance treatment. None of the demographic features was shown to be associated with a significantly increased risk of ulcer recurrence during maintenance treatment. Comparison of the recurrence rates during maintenance treatment with those during periods without active anti-ulcer therapy, using life table and incidence density analysis, showed a significant difference in favour of maintenance treatment. We conclude that maintenance treatment with ranitidine for 5 years significantly reduces the risk of symptomatic ulcer recurrence in patients with gastric ulcer.
对120例胃溃疡患者进行了回顾性研究,这些患者接受雷尼替丁(150或300毫克/天)维持治疗长达7年。维持治疗期间溃疡症状未复发的患者比例在1年后为97%;3年后为90%;5年后为79%。维持治疗期间无患者发生出血或穿孔。未发现任何人口统计学特征与维持治疗期间溃疡复发风险显著增加相关。使用生命表和发病率密度分析比较维持治疗期间与无积极抗溃疡治疗期间的复发率,结果显示维持治疗有显著差异。我们得出结论,雷尼替丁维持治疗5年可显著降低胃溃疡患者溃疡症状复发的风险。